Clinical trial · Observational
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
Pharmacogenetic Study in Hepatocellular Carcinoma Patients Underwent TACE
NCT05291338CI-TRIAL-00068339completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
evaluate the prognostic value of genetic polymorphisms in HCC Egyptian patients undergoing TACE using lipiodol and doxorubicin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Lipiodol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- HCC patients
- description
- 116 hepatocellular carcinoma patients underwent TACE
- interventionNames
- Drug: Doxorubicin
- Drug: Lipiodol
Primary outcomes (2)
- measure
- Angiopoietin (ANG-2) rs55633437.
- timeFrame
- 1 month
- description
- Gene
- measure
- Interleukin 28 B (IL28B) rs12979860.
- timeFrame
- 1 month
- description
- Gene
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Eligible patients should fulfill the following criteria: 1. A diagnosed HCC patient. 2. Age ≥20 years. 3. Patients with adequate organ function. 4. HCC not eligible for curative measures (radiofrequency, microwave and surgery). Exclusion Criteria: * Patient will be excluded for any of the following: 1. Patients refused to sign the written consent. 2. Age \> 75 years. 3. The presence of major portal vein thrombosis. 4. Extrahepatic metastases. 5. Hepatic encephalopathy. 6. Current infection. 7. Gastrointestinal bleeding within a month. 8. Uncontrolled ascites. 9. Serum bilirubin \> 3.0 mg/dl, serum albumin \< 2.8 g/dl, serum creatinine concentration \> 1.5 mg/dl, white blood cell counts \< 3,000/mm3 and platelet counts \< 30,000/mm3. 10. Patients with other types of malignancy, advanced organ failure, and advanced medical co-morbidity. 11. Pregnant females.
References
Publications (3)
- BACKGROUNDMarisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini A. ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers (Basel). 2019 Jul 20;11(7):1023. doi: 10.3390/cancers11071023. PMID 31330833
- BACKGROUNDRashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst. 2020 Jan 16;32(1):5. doi: 10.1186/s43046-020-0016-x. PMID 32372179
- DERIVEDWerida RH, Abd El Baset OA, Askar S, El-Mohamdy M, Omran GA, Hagag RS. Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms. Expert Rev Anticancer Ther. 2024 Oct;24(10):1009-1020. doi: 10.1080/14737140.2024.2391364. Epub 2024 Aug 21. PMID 39138591